FPL-12495

FPL-12495
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

FPL-12495 is a chemical compound that has been studied for its potential pharmacological effects. It is primarily known for its role as a calcium channel blocker, which means it can inhibit the influx of calcium ions through voltage-gated calcium channels in the cell membrane. This action can have various physiological effects, particularly on the cardiovascular system.

Pharmacology

FPL-12495 acts by binding to specific sites on the calcium channels, thereby preventing calcium ions from entering the cells. This can lead to a decrease in vascular smooth muscle contraction, resulting in vasodilation and a subsequent reduction in blood pressure. The compound has been of interest in the study of hypertension and other cardiovascular disorders.

Mechanism of Action

The mechanism by which FPL-12495 exerts its effects involves the blockade of L-type calcium channels. These channels are crucial for the contraction of cardiac and smooth muscle. By inhibiting these channels, FPL-12495 reduces the contractility of the heart and dilates blood vessels, which can lower blood pressure and decrease the workload on the heart.

Clinical Applications

While FPL-12495 has shown promise in preclinical studies, its clinical applications are still under investigation. It is not currently approved for use in humans, but it serves as a valuable tool in research settings to understand the role of calcium channels in various physiological and pathological processes.

Research and Development

Research on FPL-12495 has primarily focused on its potential as a therapeutic agent for cardiovascular diseases. Studies have explored its effects on cardiac arrhythmias, angina pectoris, and hypertension. However, further research is needed to fully understand its efficacy and safety profile.

Safety and Toxicology

The safety profile of FPL-12495 is not well-established, as it has not undergone extensive clinical testing. Preclinical studies suggest that, like other calcium channel blockers, it may have side effects such as hypotension, dizziness, and bradycardia. Toxicological studies are necessary to determine its potential risks and safe dosage ranges.

Also see

• Calcium channel blocker
• Hypertension
• Cardiovascular disease
• Pharmacology